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variations in body composition. Thus, variations in UCP2 pro-Fat tissue accumulation during peritoneal dialysis is associated
duction or activity may be factors contributing to adipose tissuewith a polymorphism in uncoupling protein 2.
accumulation in a subgroup of patients treated with PD. It isBackground. Chronic treatment with peritoneal dialysis
possible that the polymorphism has a similar effect in the gen-(PD) is a unique long-term metabolic procedure entailing a
eral population.continuous 24-hour supply of glucose absorbed from the dial-
ysis fluid. One common and important side effect of this treat-
ment is weight gain and accumulation of body fat stores. How-
ever, not all patients accumulate body fat mass during PD, and It has been shown that genetic factors contribute tothe reason for this is not clear. Recently, two new mitochondrial
about 70% of the variations in body mass index (BMI),uncoupling proteins (UCP2 and UCP3) have been found to
but the remaining 30% are mostly caused by environ-have thermogenic properties that suggest involvement in the
control of metabolic efficiency in humans. Moreover, recent mental factors [1]. In general, increased fat mass in obe-
results suggest that a polymorphism in the UCP2 gene may sity seems to be closely related to an imbalance between
contribute to adipose tissue accumulation through its effects fat intake and fat oxidation, whereas the relationship toon energy metabolism. It could therefore be speculated that
carbohydrate intake is much less apparent [2]. However,genetic differences in the metabolic rate might contribute to
carbohydrate ingestion stimulates glycogen storage andthe differences in the accumulation of fat tissue during PD.
Methods. Genotyping of a polymorphism in the 39 untrans- glucose oxidation while suppressing fat oxidation. Perito-
lated region of exon 8 of UCP2 was performed in 41 patients neal dialysis (PD) is an established method for treating
(53 6 2 years) with chronic renal failure for whom we had chronic renal failure (CRF), and at present, more thanprospective data on body composition (as estimated by dual-
100,000 patients with CRF are treated with this methodenergy x-ray absorptiometry) following PD. In addition, indices
using dialysis fluids with glucose as the osmotic agent.of dialysis adequacy, peritoneal glucose absorption, and urea
kinetics were followed (3 to 6 times per year in each patient) Glucose is absorbed to a large extent from the dialysate,
during treatment with PD. The degree of physical activity was and conventional PD results in an almost unique meta-
assessed before the start of PD. bolic situation involving continuous 24-hour absorptionResults. Twenty patients with the deletion/deletion UCP2
of glucose. It has been estimated that during conven-genotype had a significant increase in body weight (3.0 6 0.8
tional PD, about 100 to 200 g of glucose are absorbedvs. 21.0 6 1.1 kg, P , 0.01) and body fat mass (3.8 6 0.9 vs.
0.8 6 1.0 kg, P , 0.05) during PD, compared with 19 patients during 24 hours [3, 4], and glucose uptake from the dial-
with an insertion/deletion UCP2 genotype. On the other hand, ysis fluid represents a significant portion of the energy
no significant differences in indices of dialysis adequacy, perito- intake [5]. Weight gain and accumulation of fat tissueneal glucose absorption, urea kinetic parameters, or degree of
accompany chronic treatment with PD, but there arephysical activity were observed when comparing patients who
marked variations between patients [6–8]. It is generallyaccumulated or lost fat tissue during PD.
Conclusions. As most patients with the deletion/deletion assumed that the accumulation of adipose tissue is re-
UCP2 genotype acquired fat tissue during PD, the present lated to the glucose absorption from the dialysate, but
results suggest that the UCP2 polymorphism contributes to there is no clear relationship between the gain in weight
and the amount absorbed. Obviously, there is no way to
accumulate excess adipose tissue without disequilibriumKey words: peritoneal dialysis, uncoupling protein 2, dual-energy x-ray
absorptiometry, body fat mass, obesity. between the intake and expenditure of calories. Thus, if
the caloric intakes are similar, it seems reasonable toReceived for publication August 26, 1999
surmise that patients who accumulate body fat tissueand in revised form October 27, 1999
Accepted for publication November 1, 1999 during PD have lower metabolic rates than those who
do not gain fat mass during PD.Ó 2000 by the International Society of Nephrology
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Fig. 1. Hypothesis about the regulation of thermogenesis by uncoupling proteins (UCPs). An excess of protons (H1) is generated outside of the
mitochondrial inner membrane as electrons are moving along the electron transport chain (A). The proton excess in the intermembranous space
provides the energy to transform ADP to ATP (B). The UCPs provide an alternative route for protons to re-enter the mitochondrial matrix. The
energy conserved by proton pumping will result in heat production (C). The activity of the UCPs can be modulated by genetic factors, cold
exposure, hormones, inflammation, b3-agonists and diet (free fatty acids). FFA, free fatty acids.
Although the mechanisms behind the regulation of rate is very low [14]. Consequently, the UCP1 pathway
is of minor importance for thermogenesis in the human.energy intake and energy expenditure remain unclear,
some recent findings have contributed to a better under- However, recently two new mitochondrial uncoupling
proteins (UCP2 and UCP3) have been discoveredstanding of the regulation of body weight. It has been
found that small reductions in energy expenditure in- [15, 16]. While UCP3 expression has been found only in
skeletal muscle, UCP2 has a wide tissue distribution, andcrease the risk for developing obesity [9] and that genetic
factors may influence the resting metabolic rate [10–12]. it has been speculated that UCP2 may play a role in fat
tissue accumulation [17]. Indeed, we and others haveOne reason for increased energy expenditure appears
to entail an increased thermogenesis in brown adipose observed an impaired gene expression of UCP2 in obese
subjects that may reduce the energy expenditure andtissue. The key element in brown adipose tissue is the
unique expression of a mitochondrial inner-membrane contribute to the development and maintenance of obe-
sity [18, 19]. Moreover, Cassel et al have recently de-protein called uncoupling protein 1 (UCP1), which is a
transporter of free fatty acid anions, allowing free fatty scribed a UCP2 gene exon 8 variant that may affect
susceptibility to weight gain [20]. In this context, it is ofacids to function as proton carriers (Fig. 1). On activa-
tion, UCP1 causes the uncoupling of respiration from interest that Bouchard et al have reported a significant
linkage between microsatellite markers in the vicinity ofoxidative phosphorylation, which results in the genera-
tion of heat without driving ATP synthesis [13]. In hu- the UCP2 gene and resting metabolic rate [21]. Further-
more, Walder et al have shown that Pima Indians withmans, the contribution of brown fat to the metabolic
Nordfors et al: UCP2 polymorphism in PD 1715
the insertion/deletion UCP2 genotype in exon 8 had Weekly Kt/Vurea and weekly creatinine clearance (CCr)
(L/week/1.73 m2) were calculated from the results of thehigher metabolic rates than deletion/deletion UCP2 ge-
notype subjects [12]. On the basis of these previous find- 24-hour collections of dialysate and urine. The distribu-
tion volume of urea (V), which is generally assumed toings, we have, in the present study, investigated whether
the UCP2 polymorphism may influence changes in body equal the total body water, was calculated with V esti-
mated from the Watson equation [23]. Weekly CCr wascomposition during PD.
calculated as peritoneal CCr plus the average of renal urea
clearance and CCr. Dietary protein intake was estimatedMETHODS
from the protein equivalent of nitrogen appearance
Patients (PNA) using this recently derived equation: PNA 5
15.1 1 0.195 urea appearance (mmol/24 h) 1 proteinForty-one patients (28 males and 13 females) were
examined prior to and following about one year of PD. losses (g/24 h) [24]. Urea appearance and protein losses
were determined from the urea, and protein excretionNone of the patients were first-degree relatives. Before
starting PD, their mean age (SEM) was 53 6 2 years, which was measured in dialysate and urine. PNA was nor-
malized for actual body weight to obtain nPNA (g/kg/24 h).and their BMI was 24.3 6 0.5 kg/m2 (range 19.2 to 34.1
kg/m2). The cause of CRF was diabetic nephropathy The 24-hour peritoneal glucose absorption was calcu-
lated from the dialysate volumes and glucose concentra-in 12 (29%) patients, chronic glomerulonephritis in 15
patients (37%), polycystic kidney disease in 5 (12%), tions used during 24 hours and the directly measured
volume and glucose concentration of the drained 24-interstitial nephritis in 2 (5%), and other or unknown
etiologies in 7 (17%). Most patients were on antihyper- hour dialysate. The average values of total protein loss,
Kt/Vurea, weekly CCr, PNA, nPNA, and 24-hour glucosetensives [b-blockers, calcium channel blockers, furose-
mide, and angiotensin-converting enzyme (ACE) inhibi- absorption from all 24-hour collections of urine and dial-
ysate in each patient during the first year of PD weretors] and other commonly used drugs in terminal CRF,
such as phosphate and potassium binders, as well as used in the statistical analysis. The number of collections
varied between three and six in different patients.vitamin B, C, and D supplementation.
Protocol Estimation of physical activity
The degree of physical activity was estimated by aAfter an overnight fast, a blood sample was taken for
typing of the exon 8 variant of UCP2. Nutritional status questionnaire before the start of PD. Each patient was
given a score reflecting the degree of physical activity:was recorded on the same occasion using subjective global
assessment (SGA) as previously described [22]. Measure- 1 5 regular exercise (N 5 11), 2 5 no regular exercise
but normal physical activity (N 5 25), 3 5 low physicalments of body composition by dual-energy x-ray absorp-
tiometry (DEXA), weight, and height were performed activity (N 5 5), and 4 5 confined to bed or wheelchair
bound (N 5 0).in all patients at a time point close to the start of PD
and following about one year of PD. DEXA was always
Analysesperformed after drainage of the peritoneal dialysate, to
avoid the effect of dialysate in the peritoneal cavity on All subjects were screened for a variation in the UCP2
gene. The polymorphism consists of a 45 bp insertionthe results. Forty of the patients were initially treated
with continuous ambulatory PD (CAPD), and one of (ins) or deletion (del) in the 39-untranslated region of
exon 8. The ins variant contains a duplication of a frag-the patients was treated with automated PD (APD) using
a cycler. The dialysate volumes prescribed were individu- ment shown in upper case as follows: 59-CCCTCTTTC
CCCACCTCTTCCTTCCGCTCCTTTACCTACCACalized, and three of the patients were switched from
CAPD to APD during the 12-month period. Four pa- CTT-39. The polymorphic region was amplified with for-
ward primer 59-CAG TGA GGG AAG TGG GAG G-39tients had used one exchange of a polyglucose solution
per day during the study period, whereas no patient was and reverse primer 59-GGG GCA GGA CGA AGA
TTC-39, yielding products of 457 bp and 502 bp for thetreated with amino acid-based dialysis solutions. The
study was approved by the Ethics Committee of Karolin- deletion and insertion, respectively (Fig. 2). The PCR
products were separated on 1% agarose gels, stainedska Institute, Stockholm, Sweden. All patients gave in-
formed consent to participate in the study. with ethidium bromide and photographed under ultravi-
olet transillumination. Homozygotes for the two variants
Calculations of dialysis adequacy and urea kinetics were verified by sequencing, using an ABI Prism 377
DNA sequencer (Perkin Elmer, Foster City, CA, USA).A 24-hour collection of dialysate and urine was per-
formed soon after the start of PD and was repeated two Determinations of creatinine and urea were carried
out in the Department of Clinical Chemistry, Huddingeto five times during the first year, depending on changes
in residual renal function and dialysis prescriptions. Hospital, using routine methods. All subjects had their
Nordfors et al: UCP2 polymorphism in PD1716
Table 1. Body compositional data in patients at basal (close to start
of PD) and at follow-up in 20 del/del homozygotes and 19 ins/del
heterozygotes, respectively
Genotype Basal Follow-up
del/del UCP2
Body weight kg 69.863.0 72.863.0a
Body fat mass kg 19.061.1 22.861.7b
Lean body mass kg 49.062.4 48.762.6
ins/del UCP2
Body weight kg 77.063.2 76.063.6
Body fat mass kg 21.961.6 22.761.9
Lean body mass kg 53.962.1 51.662.1a
Abbreviation: PD; peritoneal dialysis
aP , 0.01 and bP 5 0.001 vs. Basal
RESULTS
Forty-one patients in whom we had prospective data
on body composition (as estimated by DEXA) were
typed for the UCP2 exon 8 variant. The allele frequencies
were 72% for the deletion and 28% for the insertion,
respectively. The genotype frequencies were 20/41 for
del/del, 19/41 for ins/del heterozygotes, and 2/41 for ins/
ins, a frequency similar (that is, del/del 51.3%, ins/del
40.9%, and ins/ins 7.8%) to the one observed by us
in a large (N 5 638), Swedish nonuremic population
(Nordfors et al, unpublished data). The rare ins/ins ho-
Fig. 2. Agarose gel electrophoresis with PCR products from the three mozygotes were omitted from the rest of the analysis
different genotypes. Lane 1, 100 bp ladder (GIBCO BRL, Grand Island, because only two patients had this genotype. Data onNY, USA); lane 2, del/del; lane 3, ins/del; lane 4, ins/ins.
body composition close to start of PD and after approxi-
mately 12 months of PD are shown in Table 1. No signifi-
cant differences were found in body weight, body fat
mass, or lean body mass between the two groups ofbody composition evaluated by DEXA (Lunar Radia-
UCP2 genotypes on the basal examination. Moreover,tion Corp., Madison, WI, USA) at the entrance to the
the prevalence of malnutrition (SGA . 1) was similarstudy (baseline) and following approximately one year
in del/del (40%) homozygotes and ins/del (32%) hetero-of PD. With this technique, bone mineral, fat, and lean
zygotes. However, following PD, significant increases inbody mass were directly estimated without making as-
body weight (P , 0.01) and body fat mass (P 5 0.001)sumptions of the two-compartment model [25, 26].
were observed in del/del homozygotes, while no signifi-DEXA is better than other simple noninvasive methods
cant change in lean body mass was observed in this group.for determining body composition in renal failure, partic-
In contrast, no significant changes in body weight orularly when emphasis is placed on repeated measure-
body fat mass were observed in ins/del heterozygotes,ments [27, 28]. DEXA has therefore been widely used
but a significant (P , 0.01) reduction was found in leanfor studies of body composition in PD patients [6, 29, 30].
body mass following PD. The changes in body weightHowever, it must be kept in mind that although the state
and body fat mass during PD in del/del and ins/del UCP2of hydration does not influence body fat mass, it may
genotypes, respectively, are shown in Figure 3.
affect the lean body mass.
The patients were also divided into those (N 5 28)
who accumulated body fat mass (mean 4464 6 740 g)Statistical methods
and those (N 5 13) who lost body fat mass (mean 21869 6
All results are given as mean 6 SEM. The nonpara- 579 g) during PD. No significant differences were ob-
metric Mann–Whitney U-test was used to test differences served in age, the prevalence of diabetes mellitus, the
between different patient groups. The nonparametric number of patients that took b-blockers (which may
Wilcoxon rank-sum test was used to evaluate differences affect energy expenditure), or male gender between the
over time. Comparisons between two groups of nominal two groups (Table 2). Moreover, the proportion of pa-
variables were made with Fisher’s exact test. A two- tients who took regular physical exercise, the average
peritoneal glucose absorptions, and all adequacy param-tailed P value of less than 0.05 was considered significant.
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Fig. 3. Box plots showing changes in body
weight (A) and body fat mass (B) after perito-
neal dialysis in 20 patients with the del/del
UCP2 genotype and 19 patients with the ins/
del UCP2 genotype. *P , 0.05 vs. del/del;
**P , 0.01 vs. del/del.
Table 2. Clinical characteristics, mean dialysis adequacy parameters associated with an increased continuous intraperitoneal
and the proportion del/del, ins/del and ins/ins UCP2 genotypes in
carbohydrate load, and it has been speculated that this41 patients who gained or lost fat tissue during peritoneal dialysis
may be one factor that promotes the accumulation of
Gained Lost
fat mass [31]. However, in the present study, we foundbody fat body fat
N 5 28 N 5 13 Significance no differences in the mean peritoneal glucose absorption
from the calorie-rich PD fluid between the patient groupBMI kg/m2 24.660.7 23.660.8 NS
Age years 5362 5564 NS that acquired fat tissue and the patient group that did
Male gender 18/28 9/13 NS not. Unfortunately, the methods easily available for mea-Medication with b-blockers 14/28 8/13 NS
suring caloric intake in humans are unreliable and impre-Diabetes mellitus 8/28 4/13 NS
Conducted regular physical cise [2], and caloric intake was therefore not assessed
activity 9/28 2/13 NS
during PD treatment. However, as the normalized pro-Total protein losses g/24 h 8.160.6 9.160.8 NS
Glucose absorption tein equivalent of nitrogen appearances (nPNA) was
mmol/24 h 505629 474633 NS similar in the patients who accumulated or lost adipose
nPNA g/kg 1.0260.05 1.0060.05 NS
tissue during PD, it seems unlikely that major differencesKt/V urea 2.3360.10 2.3060.17 NS
CCr L/week 8663 8267 NS in caloric intake could have contributed to the changes
Proportion del/del observed in adipose tissue. Obviously, if the caloric in-homozygotes 17/28 3/13 P , 0.05
take and peritoneal glucose absorptions were similar inProportion ins/del
heterozygotes 9/28 10/13 P , 0.05 both groups, the differences in energy expenditure must
Proportion ins/ins explain the accumulation of excess adipose tissue ob-homozygotes 2/28 0/13 not tested
served in many patients. The expenditure side of the
Abbreviations are: nPNA, normalized protein equivalent of nitrogen appear-
ance; CCr, creatinine clearance; NS, not significant. equation is generally thought of as resting metabolic rate
(which may account for about 60 to 70% of total energy
expenditure) and physical activity. Our results suggest
that differences in the degree of physical activity could
eters for dialysis were similar in patients who accumu- not have contributed to the changes observed in adipose
lated and lost adipose tissue. No significant relationships tissue during PD. Recent evidence indicates that treat-
were observed between mean 24-hour glucose absorp- ment with b-blockers decreases the whole-body meta-
tion and changes in either body weight (R 5 0.19, P 5
bolic rate, and this may be one factor that contributes to
NS) or body fat mass (R 5 0.24, P 5 NS). However,
an increase in body fat content [32]. However, our resultsalthough most patients with the del/del UCP2 genotype
suggest that treatment with b-blockers could not explainaccumulated body fat mass, less than 50% of patients
the observed changes in adipose tissue during PD.with the ins/del UCP2 genotype gained body fat mass
Although the mechanisms behind the regulation ofduring PD. Both patients with the ins/ins UCP2 genotype
energy intake and energy expenditure are unclear, recentgained body fat mass (9.3 and 0.7 kg) during PD.
findings have contributed to a better understanding of
the regulation of body weight. Much recent research has
DISCUSSION therefore focused on the potential importance of genetic
factors in the development of obesity, that is, factorsThe mechanism(s) underlying the rapid accumulation
related to DNA sequence variation. Little is knownof body fat tissue in many patients treated by PD is not
known. It is well recognized that the initiation of PD is about their function in humans, but uncoupling proteins
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may play a role in the regulation of human energy metab- the metabolic rate and body composition even in other
olism and the development of obesity by virtue of their patient populations, but that this effect may require sev-
ability to uncouple electron transport from adenosine eral years before a difference can be detected in body
59-triphosphate (ATP) synthesis (Fig. 1). It has been composition, as discussed by Walder et al [12]. Further-
calculated that the overall contribution of proton leaks to more, variations in fat intake and physical activity may
resting metabolic rate is approximately 20% [33]. Recent be much greater in the general population than in the
findings concerning the expression of UCP2 and UCP3 PD patients investigated in the present study.
at relatively high levels in a number of human tissues are In nonuremic patient populations, a marked accumu-
consistent with an important role for these uncoupling lation of abdominal fat tissue has been regarded as an
proteins [15–17]. In the present study, we found that important risk factor for cardiovascular disease [34]. In-
the del/del UCP2 genotype is associated with a greater deed, recent evidence has suggested that the strongest
tendency to accumulate fat tissue during treatment with predictors of worsening lipid profiles in CAPD patients
PD. The reason(s) for patients with the del/del UCP2 are weight gain and pre-existing cardiovascular comor-
genotype to acquire fat tissue during PD is not clear, bidity [35]. It could therefore be assumed that an accu-
but this may be due to lower energy expenditure. Unfor- mulation of fat tissue during PD treatment might also
tunately, we could not measure energy metabolism. be a significant risk factor for cardiovascular disease and
However, in a recent study by Walder et al, a significantly an increased mortality. However, to the best of our
lower sleeping metabolic rate and 24-hour energy expen- knowledge, no studies have proved that obesity and fat
diture were found in Pima Indians with the del/del UCP2 tissue accumulation are risk factors for cardiovascular
genotype than in Pima Indians with the ins/del genotype disease and death in dialysis patients. In fact, Fleisch-
[12]. They also found evidence of an association between mann et al recently showed that hemodialysis patients
UCP2 polymorphism and BMI. As the exon 8 variant is with a high BMI had a better survival than patients
located in the 39 untranslated region of the gene, it might with a normal BMI, suggesting that obesity actually may
have an effect on UCP2 mRNA stability and posttran- reduce the risk of death in dialysis patients [36]. In this
scriptional processing, thereby altering the protein pro- respect, it is noteworthy that patients who did not accu-
duction rate [12]. On the basis of these findings, it can mulate fat tissue (that is, the ins/del UCP2 genotype) in
therefore be speculated that a reduction in UCP2 mRNA the present study lost a significant amount of lean body
stability could compromise a subject’s ability to remove mass (that is, muscle mass) during PD. This finding
excess calories through thermogenesis during treatment agrees with previous studies, which have concluded that
with PD. Although the ins/del polymorphism has not some patients may be at risk of losing lean body mass
been shown to have a functional effect, it can not be
during long-term PD treatment [8, 37]. It could therefore
ruled out that it affects translation of UCP2 mRNA and
be speculated that if the ins/del UCP2 genotype is associ-protein activity [12]. Both patients who were homozy-
ated with elevated energy expenditure, the energy supplygous for the insertion gained body fat tissue during PD,
might not be sufficient to promote a positive nitrogenand if both deletion and insertion homozygotes acquire
balance, which could lead to a gradual loss of lean bodymore fat than heterozygotes, this could suggest a mutual
mass [38]. Further prospective studies are needed toreinforcing effect of the two alleles on energy expendi-
determine whether an accumulation of body fat tissueture. Alternatively, the exon 8 UCP2 polymorphism does
is associated with better or worse survival rates duringnot cause the metabolic differences, but may instead be
treatment with PD.in linkage disequilibrium with another nearby genetic
In conclusion, the present results show a considerablevariant, which has a functional effect. However, it should
contribution of the exon 8 UCP2 polymorphism to varia-be pointed out that factors other than differences in the
tions in body composition. Patients with the deletion/UCP2 genotype might also contribute to adipose tissue
deletion UCP2 genotype acquired more fat tissue duringaccumulation during PD. In fact, one of the patients
PD than did those with the insertion/deletion UCP2 ge-with the ins/del UCP2 genotype showed a pronounced
notype. Thus, variations in UCP2 production or activityaccumulation of fat mass in the present study (Fig. 3).
may be important factors contributing to fat tissue accu-We know of no clinical condition other than PD in
mulation in patients treated with PD.which such a pronounced increase in carbohydrate in-
take occurs. Moreover, a significant accumulation of fat
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